Explore Veru's Q4 2025 earnings, strategic shift to drug development, regulatory clarity, and new trials for obesity management.
Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...
Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...
Josh Brett on MSN
Who’s really using SARMs - and why it’s becoming a problem
SARMs are exploding in popularity—but they’re not approved for human use. Marketed as “legal steroids,” they’re linked to ...
The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...
A promising type of cancer care that’s largely been available only in Boston is coming to central Massachusetts. The state Public Health Council on Wednesday unanimously ...
What could force a supermassive black hole (SMBH) out of its host galaxy? They can have hundreds of millions, even billions ...
Smithsonian Magazine on MSN
Can GLP-1s Help Fat Cats Lose Weight? The First Clinical Trial Testing the Drugs for Weight Loss in Felines Has Begun
San Francisco-based pharmaceutical company OKAVA is investigating an implant that slowly releases a GLP-1 medication for up ...
Neurovalens announced that it received FDA de novo approval for Modius Lean, its non-invasive neurotechnology for weight ...
When they stopped the visit, a balloon was found in her mouth stuffed with 11 stamp-sized pieces of paper — each soaked in a synthetic drug that thrives almost exclusively behind prison walls. It’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback